Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration’s Adverse Event Reporting System, 2010-2017

IMPORTANCE: Sipuleucel-T was the first therapeutic cancer vaccine approved by the US Food and Drug Administration (FDA) in 2010. Although almost a decade has passed since its approval for the treatment of asymptomatic or minimally symptomatic castration-resistant prostate cancer (CRPC), there remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Dores, Graça M., Bryant-Genevier, Marthe, Perez-Vilar, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694390/
https://www.ncbi.nlm.nih.gov/pubmed/31411714
http://dx.doi.org/10.1001/jamanetworkopen.2019.9249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694390/
https://www.ncbi.nlm.nih.gov/pubmed/31411714
http://dx.doi.org/10.1001/jamanetworkopen.2019.9249

Ejemplares similares